source
- Novo Nordisk CFO sees oral Wegovy rollout boosting outlook and remains upbeat on CagriSemaNovo Nordisk's chief financial officer, Karsten Munk Knudsen, discussed the company's second‑quarter earnings and the progress of the oral Wegovy pill during a recent interview. He highlighted that…
- BlossomHill and Latigo Biotherapeutics raise over 30% beyond IPO targetsTwo emerging biotech companies surpassed their initial public offering expectations on Friday, with both BlossomHill Therapeutics and Latigo Biotherapeutics raising at least 30% more capital than p…